LYEL News and Press, Lyell Immunopharma Inc. From 11/08/23

Lyell Immunopharma Inc. (LYEL) is expected to report $-0.27 for Q3 2023

Extended funding of operations into 2027 by prioritizing investment in core clinical candidates and research platform value drivers as well as de-prioritizing selected early-stage research programs Remain on track to release initial clinical data from two clinical-stage product candidates in ...

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, is presenting new nonclinical data at the 38 th Annual Me...

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced today that six abstracts highlighting its broad pi...

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform PR Newswire Proof-of-concept manufacturing to be provided by Cellares for a key Lyell CAR T-cell therapy using Cellares' exclusive Cell Shuttle ...

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team wi...

2023-08-28 17:41:14 ET More on Lyell Immunopharma Lyell Immunopharma: Once Huge IPO Now Waiting For Clinical Data MaxCyte in licensing pact with Lyell Immunopharma for cell therapies FDA clears Lyell Immunopharma IND for esophageal cancer candidate Lyell Immu...

Cash, cash equivalents and marketable securities of $632.7 million as of June 30, 2023 support advancing multiple product candidates through key clinical milestones Remain on track for initial clinical data from two lead product candidates in 2024 Further strengthened executive lea...

2023-07-19 17:30:09 ET Gainers: Zions Bancorporation ( ZION ) +8% . Heritage-Crystal Clean ( HCCI ) +7% . CareMax ( CMAX ) +5% . Cabaletta  ( CABA ) +5% . AlloVir ( ALVR ) +4% . Losers: Richardson Electronics ( REL...

2023-06-16 10:47:04 ET Shares of Lyell Immunopharma (NASDAQ: LYEL) were up 39% for the week as of early Friday morning, according to data provided by S&P Global Market Intelligence . The clinical-stage biotech , which ended last week's trading at $2.78, rose to as high a...